Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2025)

Kiniksa Pharmaceuticals International's Change in Receivables history spans 5 years, with the latest figure at -$36.1 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 314.71% year-over-year to -$36.1 million; the TTM value through Dec 2025 reached -$26.1 million, down 227.73%, while the annual FY2025 figure was -$26.1 million, 227.73% down from the prior year.
  • Change in Receivables reached -$36.1 million in Q4 2025 per KNSA's latest filing, down from $19.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.5 million in Q1 2022 to a low of -$36.1 million in Q4 2025.
  • Average Change in Receivables over 5 years is $720444.4, with a median of $1.1 million recorded in 2021.
  • The largest YoY upside for Change in Receivables was 1114.19% in 2023 against a maximum downside of 744.85% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $686000.0 in 2021, then soared by 118.8% to $1.5 million in 2022, then soared by 1114.19% to $18.2 million in 2023, then dropped by 7.62% to $16.8 million in 2024, then tumbled by 314.71% to -$36.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Change in Receivables are -$36.1 million (Q4 2025), $19.8 million (Q3 2025), and -$8.2 million (Q2 2025).